Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and rituximab for relapsed/refractory central nervous system lymphoma
jRCTs031180374Suspended
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of temozolomide and rituximab in central nervous system lymphoma. Primary endpoint: Overall response rate. Started Feb 2015; status: suspended.
02
Drugs
temozolomiderituximab
03
Conditions
central nervous system lymphoma
Beyond the preview
Go deeper on jRCTs031180374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180374.